Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01527838 · ClinicalTrials.gov registry record · Phase 1
Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit
A Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT01527838: Completed Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease, sponsored by Fate Therapeutics.
NCT01527838 is a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease that has completed, run by Fate Therapeutics. The registered enrollment target is 10 participants, below the 191-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (95% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01527838, a Phase 1 study of Chronic Lymphocytic Leukemia (CLL) and Hodgkin's Disease, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.
Primary Outcome
To determine the minimally effective TNC dose for a single FT1050-treated CB unit based on neutrophil engraftment/chimerism when used for hematopoietic reconstitution following a reduced-intensity conditioning regimen for hematologic malignancies.
Conditions Studied
Interventions
- BIOLOGICAL Single FT1050 treated UCB unit
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute-Hematopoietic Stem Cell Transplant Program - Boston
Ohio
- Ohio State Univeristy Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01527838 record still lists
NCT01527838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 191-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (95% lower).
The record links to 5 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which Single FT1050 treated UCB unit is the first listed.
NCT01527838 reports a single indexed study location in Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT01527838 about?
NCT01527838 is a clinical study titled "Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit". This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial a...
What is the current status of trial NCT01527838?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2012-01. Estimated completion is 2013-11.
What conditions does trial NCT01527838 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Hodgkin's Disease, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Non-Hodgkins Lymphoma (NHL).
What interventions are being tested in trial NCT01527838?
The interventions under investigation include: Single FT1050 treated UCB unit (BIOLOGICAL).
Who is sponsoring clinical trial NCT01527838?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01527838 being conducted?
This trial has 3 study locations across Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01527838's enrollment target sits among peer trials
10 28th of 29 higher than 1 of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RECRUITING · Phase 1
-
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
ACTIVE NOT RECRUITING · Phase 1
-
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia